oxysterol binding protein like 5Genealiases: OBPH1 · ORP5
Q-omics provides the consensus-scored OSBPL5 profile across patient tissues and cancer cell-line models. OSBPL5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, OSBPL5 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, OSBPL5 protein abundance shows 24,915 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, UCEC, and LSCC as cancer lineages where OSBPL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSBPL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSBPL5 survival associations across molecular data types. OSBPL5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSBPL5 RNA expression–survival associations across cancer types. High OSBPL5 expression shows unfavorable associations in LUAD, MESO, ACC, LUSC and KICH, but favorable associations in THYM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for OSBPL5 RNA expression.
This table summarizes OSBPL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for OSBPL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSBPL5 shows lower tumor expression in UCEC, KICH, BLCA and LUSC and higher tumor expression in KIRC and LIHC. The UCEC box plot shows higher OSBPL5 RNA expression in normal versus tumor tissue (log2 FC = −1.571, t-test p < 0.001).
This table shows molecular features associated with OSBPL5 in patient tissues and cancer cell lines. In patient samples, OSBPL5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OSBPL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
